|
Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor
|
22 March 2011 |
|
Roche Annual General Meeting: dividend raised by 10%
|
01 March 2011 |
|
Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer
|
08 February 2011 |
|
The Roche Group posted solid overall results in 2010
|
02 February 2011 |
|
Roche personalized investigational medicine shows survival benefit in advanced skin cancer
|
19 January 2011 |
|
FDA grants supplemental approval for ACTEMRA
|
06 January 2011 |
|
Roche provides update on Avastin following reviews in Europe and the United States
|
16 December 2010 |
|
Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy or radiotherapy by 80%
|
05 December 2010 |
|
Roche obtains license for EGFR lung cancer assays and will develop Tarceva companion diagnostic test
|
23 November 2010 |
|
Roche announces implementation plans for its Operational Excellence Program
|
17 November 2010 |
|
Roche reports promising Phase II results with new targeted approach in advanced melanoma
|
09 November 2010 |
|
FDA approves Herceptin for HER2-positive metastatic stomach cancer
|
25 October 2010 |
|
Roche Group posts solid sales growth in first nine months
|
20 October 2010 |
|
Roche recognised as global healthcare leader in Dow Jones Sustainability Index
|
13 September 2010 |
|
Roche announces Operational Excellence initiative
|
08 September 2010 |
|
Roche acquires BioImagene, a leading provider of digital pathology laboratory solutions
|
23 August 2010 |
|
Roche posts good half year results
|
23 July 2010 |
|
Testing for Human Papillomavirus Genotypes 16 and 18 Detects Cervical Pre-Cancer Missed by Pap Test
|
09 July 2010 |
|
RoACTEMRA: New hope for children with systemic Juvenile Idiopathic Arthritis
|
21 June 2010 |
|
Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer
|
07 June 2010 |